Compare AFBI & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFBI | FATE |
|---|---|---|
| Founded | 1928 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.6M | 125.6M |
| IPO Year | 2020 | 2013 |
| Metric | AFBI | FATE |
|---|---|---|
| Price | $22.43 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 20.2K | ★ 1.7M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.42 | 29.88 |
| EPS | ★ 1.29 | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.86 | $0.91 |
| 52 Week High | $22.50 | $1.94 |
| Indicator | AFBI | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 72.09 | 75.27 |
| Support Level | $18.62 | $0.97 |
| Resistance Level | $22.47 | $1.94 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.09 | 0.03 |
| Stochastic Oscillator | 56.25 | 86.26 |
Affinity Bancshares Inc is a bank holding company. The bank provides a range of financial services, including checking and savings accounts, certificates of deposit, mortgage, commercial and consumer loans, and money transfer services, operating across parts of Georgia and offering specialized lending such as dental practice and indirect automobile loans across the Southeastern United States. Its business mainly involves accepting public deposits and investing them in real estate and commercial loans, as well as mortgage-backed securities. The company also gathers deposits nationwide through its virtual bank, FitnessBank, and uses additional funding sources such as Federal Home Loan Bank borrowings.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.